Calcium/magnesium/potassium/sodium oxybates - Jazz Pharmaceuticals
Alternative Names: Calcium, magnesium, potassium, and sodium oxybates oral solution; JZP-258; Lower sodium oxybate; LXB; Oxybate mixed salt solution – Jazz Pharmaceuticals; XywavLatest Information Update: 12 Jun 2024
Price :
$50 *
At a glance
- Originator Jazz Pharmaceuticals plc
- Class Hydroxybutyrates; Sleep disorder therapies; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cataplexy; Idiopathic hypersomnia; Narcolepsy
Most Recent Events
- 13 Apr 2024 Efficacy data from a phase III trial in Idiopathic hypersomnia presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 10 Sep 2023 Adverse events and pharmacokinetics data from a phase-I trial in healthy volunteers presented at the American College of Clinical Pharmacology (ACCP-2023)
- 22 Apr 2023 Long term adverse events data from a phase III trial in Narcolepsy with Cataplexy presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)